Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 10, Pages 3041
Publisher
MDPI AG
Online
2020-10-19
DOI
10.3390/cancers12103041
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
- (2020) Frank Kroschinsky et al. INVESTIGATIONAL NEW DRUGS
- Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study.
- (2020) Jeff P. Sharman et al. JOURNAL OF CLINICAL ONCOLOGY
- Glycosylation of Fcγ receptors influences their interaction with various IgG1 glycoforms
- (2020) Florian Cambay et al. MOLECULAR IMMUNOLOGY
- DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
- (2020) Simone C. Oostindie et al. Blood Cancer Journal
- Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy
- (2020) Katja Klausz et al. HAEMATOLOGICA
- A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
- (2020) Laurie H. Sehn et al. Journal of Hematology & Oncology
- Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
- (2020) Gilles Salles et al. LANCET ONCOLOGY
- Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism
- (2020) Marije B. Overdijk et al. MOLECULAR CANCER THERAPEUTICS
- A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma
- (2019) Ken Ohmachi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia
- (2019) Stephan Stilgenbauer et al. LEUKEMIA
- Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
- (2019) Thomas Nerreter et al. Nature Communications
- DuoMab: a novel CrossMab-based IgG-derived antibody format for enhanced antibody-dependent cell-mediated cytotoxicity
- (2019) Claudio Sustmann et al. mAbs
- Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies
- (2019) Bart ECG De Goeij et al. BLOOD
- Fcγ Receptor Activation by Human Monoclonal Antibody Aggregates
- (2019) Minoru Tada et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Optimal combination of beneficial mutations for improved ADCC effector function of aglycosylated antibodies
- (2019) Hyun Woung Yoon et al. MOLECULAR IMMUNOLOGY
- Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors
- (2019) Dennis R. Goulet et al. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
- The Fab portion of immunoglobulin G contributes to its binding to Fcγ receptor III
- (2019) Rina Yogo et al. Scientific Reports
- Antibodies to watch in 2020
- (2019) Hélène Kaplon et al. mAbs
- Antibody fucosylation lowers FcγRIIIa/CD16a affinity by limiting the conformations sampled by the N162-glycan
- (2018) Daniel J. Falconer et al. ACS Chemical Biology
- Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
- (2018) W Jurczak et al. ANNALS OF ONCOLOGY
- CD317 Signature in Head and Neck Cancer Indicates Poor Prognosis
- (2018) L.-L. Yang et al. JOURNAL OF DENTAL RESEARCH
- Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement
- (2018) Deniz Ugurlar et al. SCIENCE
- Abstract 3833: SEA-BCMA: A highly active enhanced antibody for multiple myeloma
- (2018) Heather Van Epps et al. CANCER RESEARCH
- Antigen binding allosterically promotes Fc receptor recognition
- (2018) Jun Zhao et al. mAbs
- CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
- (2018) Niels W.C.J. van de Donk et al. Frontiers in Immunology
- Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms
- (2018) Ryuta Wada et al. mAbs
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
- (2017) Umberto Vitolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile
- (2017) Christine W. Bruggeman et al. JOURNAL OF IMMUNOLOGY
- Enhancement of antibody functions through Fc multiplications
- (2017) Qun Wang et al. mAbs
- Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearance
- (2017) Migyeong Jo et al. mAbs
- IMMU-54. CD317 EXPRESSION IN HUMAN GLIOBLASTOMA: A TARGET FOR IMMUNOTHERAPY
- (2017) Dorothee Gramatzki et al. NEURO-ONCOLOGY
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modulating IgG effector function by Fc glycan engineering
- (2017) Tiezheng Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity
- (2017) Tim Wirt et al. TRANSFUSION MEDICINE AND HEMOTHERAPY
- A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries
- (2017) Katja Klausz et al. Oncotarget
- Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities
- (2017) Gillian Dekkers et al. Frontiers in Immunology
- Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent Cytotoxicity
- (2017) Benjamin Peschke et al. Frontiers in Immunology
- A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
- (2017) Stina Wichert et al. PLoS One
- Conformational effects of N-glycan core fucosylation of immunoglobulin G Fc region on its interaction with Fcγ receptor IIIa
- (2017) Yoshitake Sakae et al. Scientific Reports
- Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
- (2016) Jeff P. Sharman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunoglobulin isotype knowledge and application to Fc engineering
- (2016) Randall J Brezski et al. CURRENT OPINION IN IMMUNOLOGY
- Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa
- (2016) Alysia A. Ahmed et al. JOURNAL OF STRUCTURAL BIOLOGY
- Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen
- (2016) Guanbo Wang et al. MOLECULAR CELL
- Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies
- (2016) Marco Thomann et al. MOLECULAR IMMUNOLOGY
- Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment
- (2016) S Betrian et al. Blood Cancer Journal
- A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface
- (2016) Rob N. de Jong et al. PLOS BIOLOGY
- A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
- (2015) M. Hansson et al. CLINICAL CANCER RESEARCH
- The many faces of FcγRI: implications for therapeutic antibody function
- (2015) Jennifer F. A. Swisher et al. IMMUNOLOGICAL REVIEWS
- Structural analysis of Fc/FcγR complexes: a blueprint for antibody design
- (2015) Jose M. M. Caaveiro et al. IMMUNOLOGICAL REVIEWS
- Fcγ receptors: genetic variation, function, and disease
- (2015) Chantal E. Hargreaves et al. IMMUNOLOGICAL REVIEWS
- Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity
- (2015) Isaak Quast et al. JOURNAL OF CLINICAL INVESTIGATION
- The Structural Role of Antibody N-Glycosylation in Receptor Interactions
- (2015) Ganesh P. Subedi et al. STRUCTURE
- NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
- (2015) Wei Wang Frontiers in Immunology
- In Vitro Glycoengineering of IgG1 and Its Effect on Fc Receptor Binding and ADCC Activity
- (2015) Marco Thomann et al. PLoS One
- Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function
- (2014) Amy W. Chung et al. AIDS
- A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL
- (2014) J. A. Woyach et al. BLOOD
- Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization
- (2014) Ann L. White et al. JOURNAL OF IMMUNOLOGY
- Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity
- (2014) S. Herter et al. JOURNAL OF IMMUNOLOGY
- Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma
- (2014) Kristen N. Ganjoo et al. LEUKEMIA & LYMPHOMA
- Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia
- (2014) Carolyn M Cheney et al. mAbs
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
- (2014) C. A. Diebolder et al. SCIENCE
- A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies
- (2013) J. Deckert et al. BLOOD
- An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels
- (2013) Thies Rösner et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Human ICAM-1 Antibody Isolated by a Function-First Approach Has Potent Macrophage-Dependent Antimyeloma Activity In Vivo
- (2013) Niina Veitonmäki et al. CANCER CELL
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies
- (2013) Zhi Liu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion
- (2013) M Le Garff-Tavernier et al. LEUKEMIA
- Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
- (2013) Futa Mimoto et al. mAbs
- Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors
- (2013) Takeshi Harada et al. PLoS One
- Isotype and glycoform selection for antibody therapeutics
- (2012) Roy Jefferis ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function
- (2012) Y.-T. Tai et al. BLOOD
- Properties of mouse and human IgG receptors and their contribution to disease models
- (2012) P. Bruhns BLOOD
- Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
- (2012) Andres Forero-Torres et al. CLINICAL CANCER RESEARCH
- Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
- (2012) D. O. Persky et al. HAEMATOLOGICA
- Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis
- (2012) Thomas A. Bowden et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fc receptor engagement
- (2012) F. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies
- (2011) K.-H. Heider et al. BLOOD
- Enhanced antibody-dependent cellular phagocytosis by chimeric monoclonal antibodies with tandemly repeated Fc domains
- (2011) Hiroaki Nagashima et al. JOURNAL OF BIOSCIENCE AND BIOENGINEERING
- Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
- (2010) F. Morschhauser et al. ANNALS OF ONCOLOGY
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients
- (2010) Takahiro Ishiguro et al. CANCER SCIENCE
- B-Cell Depletion In Vitro and In Vivo with an Afucosylated Anti-CD19 Antibody
- (2010) R. Herbst et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
- (2010) Gregory L. Moore et al. mAbs
- Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding
- (2010) Damian Houde et al. MOLECULAR & CELLULAR PROTEOMICS
- In vivo biotinylation of the vasculature in B-cell lymphoma identifies BST-2 as a target for antibody-based therapy
- (2009) C. Schliemann et al. BLOOD
- A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies
- (2009) Pina M. Cardarelli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity
- (2009) Akito Natsume et al. CANCER SCIENCE
- Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcγRIIIb and MHC class II expression on the phagocytotic neutrophils
- (2009) Mami Shibata-Koyama et al. EXPERIMENTAL HEMATOLOGY
- Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
- (2009) Frédéric Bibeau et al. JOURNAL OF CLINICAL ONCOLOGY
- Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16
- (2008) Christophe de Romeuf et al. BRITISH JOURNAL OF HAEMATOLOGY
- HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody
- (2008) Wei Wang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
- (2008) A. Natsume et al. CANCER RESEARCH
- Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
- (2008) H. M. Horton et al. CANCER RESEARCH
- Terminal sugars of Fc glycans influence antibody effector functions of IgGs
- (2008) T Shantha Raju CURRENT OPINION IN IMMUNOLOGY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimization of antibody binding to Fc RIIa enhances macrophage phagocytosis of tumor cells
- (2008) J. O. Richards et al. MOLECULAR CANCER THERAPEUTICS
- Tandemly repeated Fc domain augments binding avidities of antibodies for Fcγ receptors, resulting in enhanced antibody-dependent cellular cytotoxicity
- (2008) Hiroaki Nagashima et al. MOLECULAR IMMUNOLOGY
- Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors
- (2008) S. L. Sazinsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started